 Ernesto Sparrelid
Concepts (398)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 51 | 2025 | 212 | 8.560 |
Why?
| | Liver Neoplasms | 42 | 2024 | 639 | 8.370 |
Why?
| | Liver Failure | 15 | 2025 | 91 | 5.180 |
Why?
| | Portal Vein | 24 | 2025 | 108 | 5.040 |
Why?
| | Pancreatic Neoplasms | 22 | 2025 | 880 | 4.690 |
Why?
| | Bile Duct Neoplasms | 17 | 2024 | 99 | 4.500 |
Why?
| | Pancreatectomy | 22 | 2025 | 242 | 3.650 |
Why?
| | Cholangiocarcinoma | 13 | 2024 | 77 | 3.610 |
Why?
| | Carcinoma, Pancreatic Ductal | 9 | 2025 | 269 | 3.220 |
Why?
| | Adenocarcinoma, Mucinous | 4 | 2022 | 73 | 2.910 |
Why?
| | Colorectal Neoplasms | 17 | 2022 | 749 | 2.770 |
Why?
| | Liver | 23 | 2025 | 1842 | 2.490 |
Why?
| | Embolization, Therapeutic | 6 | 2024 | 207 | 2.270 |
Why?
| | Liver Regeneration | 8 | 2025 | 40 | 2.030 |
Why?
| | Carcinoma, Hepatocellular | 8 | 2024 | 272 | 1.880 |
Why?
| | Klatskin Tumor | 10 | 2024 | 14 | 1.820 |
Why?
| | Pancreaticoduodenectomy | 10 | 2024 | 158 | 1.590 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2022 | 11 | 1.590 |
Why?
| | Postoperative Complications | 31 | 2025 | 2477 | 1.400 |
Why?
| | Retrospective Studies | 61 | 2025 | 14522 | 1.400 |
Why?
| | Bile Ducts, Intrahepatic | 7 | 2024 | 65 | 1.380 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2025 | 25 | 1.320 |
Why?
| | Biliary Tract Neoplasms | 3 | 2023 | 25 | 1.130 |
Why?
| | Pancreatic Fistula | 6 | 2025 | 27 | 1.100 |
Why?
| | Neoadjuvant Therapy | 7 | 2025 | 379 | 1.070 |
Why?
| | Bone Marrow Transplantation | 15 | 2000 | 277 | 1.000 |
Why?
| | Aged | 49 | 2025 | 22061 | 0.990 |
Why?
| | Humans | 131 | 2025 | 129625 | 0.960 |
Why?
| | Cysts | 1 | 2025 | 109 | 0.880 |
Why?
| | Middle Aged | 55 | 2025 | 31136 | 0.880 |
Why?
| | Gallbladder Neoplasms | 2 | 2023 | 21 | 0.870 |
Why?
| | Ligation | 12 | 2021 | 87 | 0.850 |
Why?
| | Prognosis | 17 | 2025 | 3774 | 0.840 |
Why?
| | Liver Diseases | 3 | 2025 | 290 | 0.810 |
Why?
| | Sweden | 11 | 2025 | 93 | 0.710 |
Why?
| | Metastasectomy | 1 | 2021 | 19 | 0.710 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 276 | 0.690 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 1560 | 0.670 |
Why?
| | Robotic Surgical Procedures | 4 | 2025 | 115 | 0.650 |
Why?
| | Adult | 44 | 2025 | 35599 | 0.640 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2512 | 0.630 |
Why?
| | Carcinoma | 1 | 2021 | 214 | 0.620 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 181 | 0.610 |
Why?
| | Male | 55 | 2025 | 63670 | 0.590 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1271 | 0.570 |
Why?
| | Liver Function Tests | 4 | 2022 | 112 | 0.560 |
Why?
| | Female | 54 | 2025 | 68734 | 0.550 |
Why?
| | Stem Cell Transplantation | 2 | 2015 | 164 | 0.520 |
Why?
| | Laparoscopy | 4 | 2024 | 450 | 0.510 |
Why?
| | Hepatitis B virus | 1 | 2016 | 36 | 0.500 |
Why?
| | Adenoviridae Infections | 1 | 2015 | 17 | 0.490 |
Why?
| | Liver Transplantation | 3 | 2021 | 833 | 0.490 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 761 | 0.480 |
Why?
| | Risk Factors | 20 | 2025 | 9786 | 0.460 |
Why?
| | Adenoviridae | 1 | 2015 | 193 | 0.460 |
Why?
| | Health Services Accessibility | 1 | 2021 | 903 | 0.450 |
Why?
| | Survival Rate | 12 | 2025 | 1872 | 0.450 |
Why?
| | Hypertrophy | 3 | 2024 | 122 | 0.430 |
Why?
| | Pancreatitis, Chronic | 2 | 2024 | 51 | 0.430 |
Why?
| | Organ Size | 4 | 2025 | 446 | 0.430 |
Why?
| | Prospective Studies | 11 | 2025 | 7135 | 0.420 |
Why?
| | Lymph Nodes | 5 | 2024 | 472 | 0.420 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 320 | 0.420 |
Why?
| | Adenocarcinoma | 3 | 2024 | 893 | 0.410 |
Why?
| | Aged, 80 and over | 12 | 2025 | 7052 | 0.390 |
Why?
| | Disease Outbreaks | 1 | 2015 | 349 | 0.390 |
Why?
| | Leucovorin | 5 | 2025 | 70 | 0.390 |
Why?
| | Pancreatitis | 2 | 2022 | 129 | 0.360 |
Why?
| | Margins of Excision | 3 | 2021 | 38 | 0.360 |
Why?
| | Serum Albumin | 2 | 2022 | 149 | 0.340 |
Why?
| | Cholangitis, Sclerosing | 2 | 2021 | 71 | 0.340 |
Why?
| | Follow-Up Studies | 10 | 2025 | 4894 | 0.340 |
Why?
| | Scandinavian and Nordic Countries | 4 | 2024 | 12 | 0.340 |
Why?
| | Biliary Tract | 2 | 2021 | 15 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 6 | 2025 | 3394 | 0.330 |
Why?
| | Fluorouracil | 4 | 2025 | 197 | 0.330 |
Why?
| | Neoplasm Staging | 4 | 2024 | 1282 | 0.320 |
Why?
| | Treatment Outcome | 17 | 2025 | 10219 | 0.300 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2025 | 958 | 0.290 |
Why?
| | Radionuclide Imaging | 3 | 2022 | 122 | 0.270 |
Why?
| | Intention to Treat Analysis | 2 | 2024 | 68 | 0.270 |
Why?
| | Contrast Media | 4 | 2025 | 393 | 0.270 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 87 | 0.270 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 855 | 0.260 |
Why?
| | Indocyanine Green | 2 | 2023 | 19 | 0.260 |
Why?
| | T-Lymphocyte Subsets | 3 | 2024 | 412 | 0.250 |
Why?
| | Lymph Node Excision | 2 | 2024 | 164 | 0.250 |
Why?
| | Transplantation, Autologous | 4 | 2023 | 213 | 0.250 |
Why?
| | Bacteremia | 5 | 2013 | 194 | 0.250 |
Why?
| | Survival Analysis | 5 | 2021 | 1269 | 0.250 |
Why?
| | Quinolines | 2 | 2024 | 156 | 0.240 |
Why?
| | Digestive System Surgical Procedures | 2 | 2024 | 96 | 0.240 |
Why?
| | Propensity Score | 2 | 2024 | 264 | 0.240 |
Why?
| | Gallbladder Diseases | 1 | 2024 | 10 | 0.230 |
Why?
| | Mesenteric Veins | 1 | 2025 | 18 | 0.230 |
Why?
| | Failure to Rescue, Health Care | 1 | 2024 | 3 | 0.230 |
Why?
| | Liver Cirrhosis | 2 | 2024 | 281 | 0.230 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 22 | 0.230 |
Why?
| | Operative Time | 1 | 2024 | 124 | 0.220 |
Why?
| | Duodenal Neoplasms | 1 | 2024 | 21 | 0.220 |
Why?
| | Blood Loss, Surgical | 1 | 2024 | 93 | 0.220 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2024 | 27 | 0.220 |
Why?
| | Ampulla of Vater | 1 | 2024 | 39 | 0.220 |
Why?
| | Registries | 4 | 2024 | 1899 | 0.210 |
Why?
| | Pancreas | 5 | 2024 | 303 | 0.210 |
Why?
| | Patient Outcome Assessment | 1 | 2024 | 126 | 0.210 |
Why?
| | Cholangitis | 1 | 2023 | 20 | 0.210 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2023 | 63 | 0.210 |
Why?
| | Warfare | 1 | 2023 | 65 | 0.210 |
Why?
| | Delphi Technique | 1 | 2024 | 225 | 0.210 |
Why?
| | Hyperemia | 1 | 2023 | 48 | 0.210 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 20 | 0.200 |
Why?
| | Antiviral Agents | 4 | 2015 | 715 | 0.200 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2023 | 67 | 0.200 |
Why?
| | Carcinoma, Papillary | 1 | 2023 | 77 | 0.200 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 98 | 0.200 |
Why?
| | Hemostatics | 1 | 2022 | 50 | 0.190 |
Why?
| | alpha 1-Antitrypsin | 1 | 2023 | 107 | 0.190 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2021 | 22 | 0.190 |
Why?
| | Fibrinogen | 1 | 2022 | 163 | 0.190 |
Why?
| | Hepatic Veins | 2 | 2022 | 31 | 0.190 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2021 | 27 | 0.190 |
Why?
| | DNA, Viral | 3 | 2015 | 347 | 0.180 |
Why?
| | Pancreatic Cyst | 1 | 2021 | 52 | 0.180 |
Why?
| | Ablation Techniques | 1 | 2021 | 35 | 0.180 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1499 | 0.180 |
Why?
| | Surgeons | 1 | 2025 | 264 | 0.180 |
Why?
| | Mycoses | 2 | 1998 | 72 | 0.170 |
Why?
| | Intraoperative Care | 1 | 2020 | 46 | 0.170 |
Why?
| | Camptothecin | 1 | 2021 | 110 | 0.170 |
Why?
| | Bevacizumab | 1 | 2021 | 128 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2013 | 402 | 0.170 |
Why?
| | Cytomegalovirus Infections | 4 | 1998 | 189 | 0.170 |
Why?
| | Sarcopenia | 1 | 2021 | 74 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 851 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 740 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2021 | 160 | 0.170 |
Why?
| | Incidence | 8 | 2024 | 2641 | 0.160 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 442 | 0.160 |
Why?
| | Time Factors | 8 | 2024 | 6555 | 0.160 |
Why?
| | Bacterial Infections | 2 | 1998 | 235 | 0.160 |
Why?
| | Neutropenia | 2 | 2013 | 137 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2019 | 282 | 0.150 |
Why?
| | Receptors, KIR | 1 | 2019 | 96 | 0.150 |
Why?
| | Adipose Tissue | 1 | 2022 | 591 | 0.150 |
Why?
| | Hepatocyte Growth Factor | 1 | 2018 | 34 | 0.150 |
Why?
| | Neoplasm Invasiveness | 1 | 2019 | 481 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 427 | 0.140 |
Why?
| | Europe | 3 | 2024 | 363 | 0.140 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 376 | 0.140 |
Why?
| | HLA Antigens | 1 | 2019 | 234 | 0.140 |
Why?
| | Epidermal Growth Factor | 1 | 2018 | 169 | 0.140 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 1997 | 3 | 0.140 |
Why?
| | Catheter Ablation | 1 | 2021 | 336 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 566 | 0.140 |
Why?
| | Respirovirus Infections | 1 | 1997 | 23 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2019 | 400 | 0.140 |
Why?
| | Curriculum | 1 | 2024 | 920 | 0.140 |
Why?
| | Thyrotropin | 3 | 2021 | 109 | 0.140 |
Why?
| | Influenza B virus | 1 | 1997 | 37 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 204 | 0.140 |
Why?
| | Graft Survival | 3 | 1998 | 513 | 0.130 |
Why?
| | Th2 Cells | 2 | 1997 | 171 | 0.130 |
Why?
| | Constriction, Pathologic | 1 | 2017 | 234 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2025 | 377 | 0.130 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1997 | 170 | 0.130 |
Why?
| | Clinical Competence | 1 | 2024 | 1017 | 0.130 |
Why?
| | Virus Diseases | 2 | 2016 | 210 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1198 | 0.130 |
Why?
| | Multicenter Studies as Topic | 3 | 2022 | 286 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1501 | 0.130 |
Why?
| | Ribavirin | 1 | 1997 | 91 | 0.130 |
Why?
| | Postoperative Period | 3 | 2023 | 330 | 0.130 |
Why?
| | Cytokines | 3 | 2004 | 2021 | 0.130 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 426 | 0.130 |
Why?
| | Logistic Models | 1 | 2021 | 1986 | 0.120 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 120 | 0.120 |
Why?
| | Cytosine | 1 | 2015 | 48 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 339 | 0.120 |
Why?
| | Hepatitis B | 1 | 2016 | 66 | 0.120 |
Why?
| | Gaucher Disease | 1 | 1995 | 6 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 530 | 0.120 |
Why?
| | Inflammation | 2 | 2022 | 2750 | 0.120 |
Why?
| | Organophosphonates | 1 | 2015 | 91 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 791 | 0.120 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 48 | 0.120 |
Why?
| | Interleukin-6 | 2 | 2018 | 723 | 0.120 |
Why?
| | Sepsis | 2 | 2004 | 575 | 0.120 |
Why?
| | Opportunistic Infections | 1 | 1995 | 46 | 0.110 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5415 | 0.110 |
Why?
| | Japan | 2 | 2025 | 98 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2022 | 1167 | 0.110 |
Why?
| | Quality of Life | 5 | 2024 | 2688 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1001 | 0.110 |
Why?
| | Fungemia | 1 | 2013 | 4 | 0.110 |
Why?
| | Reoperation | 1 | 2016 | 541 | 0.110 |
Why?
| | Cholecystectomy | 2 | 2024 | 59 | 0.110 |
Why?
| | Gadolinium DTPA | 2 | 2025 | 51 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2013 | 576 | 0.110 |
Why?
| | Graft Rejection | 1 | 1997 | 598 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1491 | 0.100 |
Why?
| | Bile Ducts | 2 | 2024 | 68 | 0.100 |
Why?
| | Graft vs Host Disease | 8 | 2000 | 240 | 0.100 |
Why?
| | Phenotype | 4 | 2024 | 3075 | 0.100 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5075 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 858 | 0.100 |
Why?
| | Child, Preschool | 12 | 2013 | 10490 | 0.090 |
Why?
| | Phylogeny | 1 | 2015 | 850 | 0.090 |
Why?
| | Risk Assessment | 3 | 2025 | 3262 | 0.090 |
Why?
| | Influenza, Human | 1 | 1997 | 601 | 0.090 |
Why?
| | Lung Diseases, Interstitial | 1 | 1997 | 610 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2018 | 2708 | 0.090 |
Why?
| | Viridans Streptococci | 2 | 2013 | 6 | 0.080 |
Why?
| | Obesity | 1 | 2022 | 2882 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 1947 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 2133 | 0.080 |
Why?
| | Lymphoproliferative Disorders | 1 | 2009 | 54 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 627 | 0.080 |
Why?
| | Herpesvirus 4, Human | 1 | 2009 | 156 | 0.070 |
Why?
| | Leukemia | 4 | 1998 | 229 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2009 | 95 | 0.070 |
Why?
| | Anti-Infective Agents | 3 | 2013 | 247 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1035 | 0.070 |
Why?
| | Tumor Burden | 2 | 2021 | 286 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5426 | 0.070 |
Why?
| | Infant | 8 | 2013 | 8995 | 0.070 |
Why?
| | Hematologic Diseases | 2 | 1998 | 62 | 0.070 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1936 | 0.060 |
Why?
| | Child | 11 | 2013 | 20884 | 0.060 |
Why?
| | Norway | 2 | 2016 | 42 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1365 | 0.060 |
Why?
| | Conversion to Open Surgery | 1 | 2025 | 15 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 611 | 0.060 |
Why?
| | Histocompatibility Testing | 4 | 1998 | 120 | 0.060 |
Why?
| | Albumins | 1 | 2025 | 103 | 0.060 |
Why?
| | Preoperative Period | 1 | 2024 | 115 | 0.060 |
Why?
| | Adolescent | 10 | 2022 | 20412 | 0.060 |
Why?
| | Capecitabine | 1 | 2024 | 45 | 0.050 |
Why?
| | Israel | 1 | 2023 | 46 | 0.050 |
Why?
| | Lactates | 1 | 2024 | 86 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2025 | 164 | 0.050 |
Why?
| | Paclitaxel | 1 | 2025 | 217 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Bilirubin | 1 | 2024 | 96 | 0.050 |
Why?
| | Amphotericin B | 2 | 2013 | 29 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 23 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 503 | 0.050 |
Why?
| | Candidiasis | 2 | 2013 | 57 | 0.050 |
Why?
| | Keratin-19 | 1 | 2023 | 3 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 98 | 0.050 |
Why?
| | Amylases | 1 | 2022 | 17 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 179 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2025 | 557 | 0.050 |
Why?
| | Hepatomegaly | 1 | 2022 | 5 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 102 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2023 | 128 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 216 | 0.050 |
Why?
| | Acute Disease | 2 | 2022 | 979 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 80 | 0.050 |
Why?
| | Pancreaticojejunostomy | 1 | 2022 | 8 | 0.050 |
Why?
| | Abdomen | 1 | 2022 | 118 | 0.050 |
Why?
| | Ceramides | 1 | 2022 | 112 | 0.050 |
Why?
| | Regression Analysis | 1 | 2024 | 997 | 0.050 |
Why?
| | Vascular Surgical Procedures | 1 | 2025 | 295 | 0.050 |
Why?
| | Bismuth | 1 | 2021 | 1 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 618 | 0.050 |
Why?
| | Endoscopy | 1 | 2024 | 288 | 0.050 |
Why?
| | Anemia, Aplastic | 3 | 1997 | 36 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 302 | 0.050 |
Why?
| | Drainage | 1 | 2022 | 164 | 0.040 |
Why?
| | Population Surveillance | 1 | 2024 | 439 | 0.040 |
Why?
| | Neutrophils | 3 | 2021 | 1210 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 262 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2021 | 219 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 266 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2020 | 220 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2020 | 151 | 0.040 |
Why?
| | Cytomegalovirus | 2 | 1997 | 154 | 0.040 |
Why?
| | Receptors, KIR2DL3 | 1 | 2019 | 9 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 712 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 730 | 0.040 |
Why?
| | Asia | 1 | 2019 | 58 | 0.040 |
Why?
| | South America | 1 | 2019 | 58 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 257 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 1998 | 53 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1998 | 58 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2020 | 349 | 0.040 |
Why?
| | North America | 1 | 2019 | 292 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2004 | 546 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 62 | 0.040 |
Why?
| | Aspirin | 1 | 2021 | 380 | 0.040 |
Why?
| | Palliative Care | 1 | 2024 | 702 | 0.040 |
Why?
| | Hepatitis, Viral, Human | 1 | 1997 | 25 | 0.040 |
Why?
| | Preoperative Care | 1 | 2020 | 338 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 1997 | 29 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 1998 | 223 | 0.030 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 60 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1432 | 0.030 |
Why?
| | Patients | 1 | 2019 | 169 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 362 | 0.030 |
Why?
| | Transplantation Conditioning | 1 | 1998 | 166 | 0.030 |
Why?
| | Metabolic Diseases | 2 | 1995 | 104 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1592 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 621 | 0.030 |
Why?
| | Liver Failure, Acute | 1 | 1997 | 66 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 1997 | 202 | 0.030 |
Why?
| | Young Adult | 3 | 2024 | 12455 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2021 | 1875 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2564 | 0.030 |
Why?
| | Ethanol | 1 | 2021 | 591 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1997 | 179 | 0.030 |
Why?
| | Eye Neoplasms | 1 | 2016 | 16 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 617 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1219 | 0.030 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 207 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1996 | 130 | 0.030 |
Why?
| | 4-Quinolones | 1 | 1995 | 2 | 0.030 |
Why?
| | Tomography | 1 | 1995 | 24 | 0.030 |
Why?
| | Phosphoproteins | 1 | 1997 | 335 | 0.030 |
Why?
| | Splenectomy | 1 | 1995 | 58 | 0.030 |
Why?
| | Wilms Tumor | 1 | 2016 | 78 | 0.030 |
Why?
| | Administration, Oral | 1 | 1997 | 787 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 876 | 0.030 |
Why?
| | Anthropometry | 1 | 1995 | 204 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1418 | 0.030 |
Why?
| | Fluconazole | 1 | 2013 | 18 | 0.030 |
Why?
| | Enterococcus | 1 | 2013 | 22 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2023 | 1613 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 30 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2013 | 45 | 0.030 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2013 | 64 | 0.030 |
Why?
| | Monocytes | 1 | 1996 | 553 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1891 | 0.030 |
Why?
| | Spleen | 1 | 1995 | 509 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 287 | 0.020 |
Why?
| | Hepatitis C | 1 | 1995 | 243 | 0.020 |
Why?
| | Radiography | 1 | 1995 | 797 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 819 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2019 | 898 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 869 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 2013 | 148 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3378 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 3968 | 0.020 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1366 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2274 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1996 | 836 | 0.020 |
Why?
| | Animals | 2 | 2023 | 35391 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1996 | 1125 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 389 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 86 | 0.020 |
Why?
| | Melanoma | 1 | 2016 | 730 | 0.020 |
Why?
| | Foscarnet | 2 | 1998 | 19 | 0.020 |
Why?
| | Macrophages | 1 | 1996 | 1488 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 164 | 0.020 |
Why?
| | Apoptosis | 1 | 1997 | 2492 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2373 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2627 | 0.020 |
Why?
| | Viral Load | 1 | 2009 | 449 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2009 | 230 | 0.020 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1998 | 118 | 0.020 |
Why?
| | Bone Marrow | 2 | 1998 | 273 | 0.020 |
Why?
| | Tissue Donors | 2 | 2000 | 391 | 0.020 |
Why?
| | Interleukin-1 | 2 | 2004 | 961 | 0.020 |
Why?
| | Mice | 1 | 2023 | 16961 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2004 | 4084 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2004 | 264 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2000 | 50 | 0.010 |
Why?
| | Age Factors | 2 | 1998 | 3152 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2000 | 42 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2000 | 54 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 2000 | 76 | 0.010 |
Why?
| | Tissue and Organ Harvesting | 1 | 2000 | 71 | 0.010 |
Why?
| | Cadaver | 1 | 2000 | 308 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1202 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 1998 | 34 | 0.010 |
Why?
| | Acyclovir | 1 | 1998 | 99 | 0.010 |
Why?
| | Ganciclovir | 1 | 1997 | 52 | 0.010 |
Why?
| | Leukemia, Myeloid | 1 | 1997 | 45 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2000 | 1203 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 1998 | 646 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 326 | 0.010 |
Why?
| | Probability | 1 | 1997 | 306 | 0.010 |
Why?
| | Exotoxins | 1 | 1996 | 15 | 0.010 |
Why?
| | Streptococcus | 1 | 1996 | 27 | 0.010 |
Why?
| | Lymphokines | 1 | 1996 | 127 | 0.010 |
Why?
| | CD3 Complex | 1 | 1996 | 102 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 155 | 0.010 |
Why?
| | Th1 Cells | 1 | 1996 | 137 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 254 | 0.010 |
Why?
| | Blood Platelets | 1 | 1998 | 382 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 281 | 0.010 |
Why?
| | Anemia | 1 | 1995 | 161 | 0.010 |
Why?
| | Biopsy | 1 | 1997 | 1088 | 0.010 |
Why?
| | Down-Regulation | 1 | 1996 | 636 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1996 | 877 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1996 | 1109 | 0.010 |
Why?
| | Liposomes | 1 | 1993 | 171 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2455 | 0.000 |
Why?
|
|
Sparrelid's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|